Dashboard
Manage Tickers

GILDGILEAD SCIENCES, INC.

Nasdaq gilead.com


$ 64.28 $ 0.19 (0.3 %)    

Friday, 31-May-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ -0.84 (-0.19 %)
DIA $ 398.57 $ 6.05 (1.59 %)
SPY $ 530.36 $ 4.76 (0.91 %)
TLT $ 91.26 $ 0.61 (0.68 %)
GLD $ 225.37 $ -1.27 (-0.59 %)
$ 64.27
$ 62.63
$ 64.14 x 100
$ 85.02 x 100
$ 62.15 - $ 64.28
$ 62.07 - $ 86.97
14,509,333
na
80.14B
$ 0.34
$ 165.25
TBD
na
na ($ 0.05)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-23-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-04-2023 06-30-2023 10-Q
5 05-03-2023 03-31-2023 10-Q
6 02-22-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-25-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 02-26-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-06-2018 06-30-2018 10-Q
25 05-09-2018 03-31-2018 10-Q
26 02-27-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-07-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 02-27-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-05-2016 06-30-2016 10-Q
33 05-06-2016 03-31-2016 10-Q
34 02-24-2016 12-31-2015 10-K
35 11-04-2015 09-30-2015 10-Q
36 08-05-2015 06-30-2015 10-Q
37 05-08-2015 03-31-2015 10-Q
38 02-25-2015 12-31-2014 10-K
39 11-05-2014 09-30-2014 10-Q
40 08-04-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Gilead And Arcus Announced Etrumadenant Pl...
06/02/2024 14:36:05

Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced new data from Cohort B of ARC-9, a ...

gileads-trodelvy-fails-to-hit-primary-goal-in-late-stage-study-with-most-common-type-of-bladder-cancer
Gilead's Trodelvy Fails To Hit Primary Goa...
05/31/2024 13:27:46

Gilead Sciences' announced topline results from the Phase 3 TROPiCS-04 study on Trodelvy for metastatic urothelial cancer. ...

gilead-sciences-to-present-evoke-01-study-results-in-metastatic-nsclc-at-an-oral-session-at-asco-2024
Gilead Sciences To Present EVOKE-01 Study ...
05/31/2024 12:16:31

– Simultaneously Published by the Journal of Clinical Oncology –Gilead Sciences, Inc. (NASDAQ:GILD) today announced detailed re...

gilead-sciences-announces-topline-results-from-phase-3-tropics-04-study-in-metastatic-urothelial-cancer-trodelvy-fails-to-meet-primary-endpoint-of-overall-survival
Gilead Sciences Announces Topline Results ...
05/30/2024 20:45:43

100-invested-in-this-stock-20-years-ago-would-be-worth-800-today
$100 Invested In This Stock 20 Years Ago W...
05/21/2024 21:30:39

gileads-recently-acquired-liver-disease-candidate-shows-improvements-in-disease-progression-and-associated-itch
Gilead's Recently Acquired Liver Disease C...
05/20/2024 13:36:16

Gilead Sciences reports interim results from the ASSURE study of seladelpar in primary biliary cholangitis, showing significant...

reported-saturday-gilead-sciences-announced-that-the-investigational-seladelpar-shows-significant-improvements-in-liver-disease-progression-and-itch-reduction-in-primary-biliary-cholangitis
Reported Saturday, Gilead Sciences Announc...
05/20/2024 05:59:36

- 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normaliz...

market-whales-and-their-recent-bets-on-gild-options
Market Whales and Their Recent Bets on GIL...
05/15/2024 17:46:45

decoding-gilead-sciencess-options-activity-whats-the-big-picture
Decoding Gilead Sciences's Options Activit...
05/10/2024 17:52:29

1000-invested-in-this-stock-20-years-ago-would-be-worth-9300-today
$1000 Invested In This Stock 20 Years Ago ...
05/07/2024 18:30:46

gilead-sciences-unusual-options-activity-for-may-06
Gilead Sciences Unusual Options Activity F...
05/06/2024 19:15:54

how-is-the-market-feeling-about-gilead-sciences
How Is The Market Feeling About Gilead Sci...
05/06/2024 13:15:15

barclays-maintains-equal-weight-on-gilead-sciences-lowers-price-target-to-76
Barclays Maintains Equal-Weight on Gilead ...
04/29/2024 15:29:57

Barclays analyst Carter Gould maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and lowers the price target from $...

will-earnings-cheer-continue-to-buoy-markets-apple-amazon-pfizer-coinbase-lead-flurry-of-q1-reports-this-week
Will Earnings Cheer Continue To Buoy Marke...
04/29/2024 05:51:21

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...

gilead-sciences-unusual-options-activity
Gilead Sciences Unusual Options Activity
04/26/2024 19:15:47

td-cowen-maintains-buy-on-gilead-sciences-lowers-price-target-to-85
TD Cowen Maintains Buy on Gilead Sciences,...
04/26/2024 17:25:25

TD Cowen analyst Tyler Van Buren maintains Gilead Sciences (NASDAQ:GILD) with a Buy and lowers the price target from $90 to ...

morgan-stanley-maintains-equal-weight-on-gilead-sciences-lowers-price-target-to-78
Morgan Stanley Maintains Equal-Weight on G...
04/26/2024 16:42:39

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and lowers the price tar...

rbc-capital-maintains-sector-perform-on-gilead-sciences-lowers-price-target-to-74
RBC Capital Maintains Sector Perform on Gi...
04/26/2024 15:46:21

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and lowers the price target...

fda-approves-biktarvy-label-update-with-data-for-pregnant-adults-with-hiv-perinatal-guidelines-recognize-biktarvy-as-alternative-regimen-for-use-during-pregnancy-and-for-those-trying-to-conceive
FDA Approves Biktarvy Label Update With Da...
04/26/2024 12:05:55

– Additional Data in Pregnant Adults Who Are Virologically Suppressed Reinforce Safety and Tolerability Profile of Biktarvy in ...

needham-reiterates-hold-on-gilead-sciences
Needham Reiterates Hold on Gilead Sciences
04/26/2024 10:21:04

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:GILD) with a Hold.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION